GSK-HZC112206



A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared with Placebo in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
fluticasone furoate/vilanterol
HZC112206
NCT01053988
Pulmonary Disease, Chronic Obstructive
Phase 3
 
September 2013